淋巴水肿的未来：治疗的潜在靶点
The Future of Lymphedema: Potential Therapeutic Targets for Treatment.
作者信息
Brown Stav, Campbell Adana C, Kuonqui Kevin, Sarker Ananta, Park Hyeung Ju, Shin Jinyeon, Kataru Raghu P, Coriddi Michelle, Dayan Joseph H, Mehrara Babak J
机构信息
Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 USA.
出版信息
Curr Breast Cancer Rep. 2023 Jun 1:1-9. doi: 10.1007/s12609-023-00491-5.
PURPOSE OF REVIEW
This review aims to summarize the current knowledge regarding the pharmacological interventions studied in both experimental and clinical trials for secondary lymphedema.
RECENT FINDINGS
Lymphedema is a progressive disease that results in tissue swelling, pain, and functional disability. The most common cause of secondary lymphedema in developed countries is an iatrogenic injury to the lymphatic system during cancer treatment. Despite its high incidence and severe sequelae, lymphedema is usually treated with palliative options such as compression and physical therapy. However, recent studies on the pathophysiology of lymphedema have explored pharmacological treatments in preclinical and early phase clinical trials.
SUMMARY
Many potential treatment options for lymphedema have been explored throughout the past two decades including systemic agents and topical approaches to decrease the potential toxicity of systemic treatment. Treatment strategies including lymphangiogenic factors, anti-inflammatory agents, and anti-fibrotic therapies may be used independently or in conjunction with surgical approaches.
综述目的
本综述旨在总结目前在继发性淋巴水肿的实验和临床试验中所研究的药物干预方面的知识。
最新发现
淋巴水肿是一种进行性疾病，会导致组织肿胀、疼痛和功能障碍。在发达国家，继发性淋巴水肿最常见的原因是癌症治疗期间对淋巴系统的医源性损伤。尽管其发病率高且后遗症严重，但淋巴水肿通常采用诸如压迫和物理治疗等姑息性方法进行治疗。然而，最近关于淋巴水肿病理生理学的研究在临床前和早期临床试验中探索了药物治疗方法。
总结
在过去二十年中，已经探索了许多针对淋巴水肿的潜在治疗选择，包括全身性药物和局部治疗方法，以降低全身治疗的潜在毒性。包括淋巴管生成因子、抗炎药物和抗纤维化疗法在内的治疗策略可以单独使用，也可以与手术方法联合使用。
Zotero 插件